Prime Medicine receives FDA clearance to run first prime editing clinical trial
The FDA has OK’d the first-ever human trial of prime editing, Prime Medicine announced Monday, opening the door for testing a new technology that backers hope will widen the array of diseases that can be treated with gene editing.
Prime’s experimental therapy, PM359, is a treatment for chronic granulomatous disease (CGD), a rare genetic condition in which phagocytes — a white blood cell type important for fighting infections — don’t work properly. Typically diagnosed in early childhood, it can cause people to get seriously ill from bacteria or fungi that normally would cause few or no symptoms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
